Khalaj K, Jacobs M, Zhu J, Esquenazi Y, Hsu S, Tandon N
Cancers (Basel). 2024; 16(13).
PMID: 39001500
PMC: 11240552.
DOI: 10.3390/cancers16132440.
Gao M, Wang X, Wang X, Niu G, Liu X, Zhao S
Cancer Sci. 2023; 115(2):589-599.
PMID: 38146096
PMC: 10859604.
DOI: 10.1111/cas.16053.
Castelli B, Fonte C, Guidi M, Tellini M, Di Nicola M, Iacono A
Front Oncol. 2023; 13:1244628.
PMID: 37799478
PMC: 10547897.
DOI: 10.3389/fonc.2023.1244628.
Ji X, Wang L, Tan Y, Shang Y, Huo R, Fang C
Oncol Lett. 2023; 26(2):361.
PMID: 37545620
PMC: 10398635.
DOI: 10.3892/ol.2023.13947.
Zhuo X, Zhao H, Chen M, Mu Y, Li Y, Cai J
Radiat Oncol. 2023; 18(1):43.
PMID: 36859353
PMC: 9979431.
DOI: 10.1186/s13014-023-02235-2.
The relationship between radiation dose and bevacizumab-related imaging abnormality in patients with brain tumors: A voxel-wise normal tissue complication probability (NTCP) analysis.
Salans M, Houri J, Karunamuni R, Hopper A, Delfanti R, Seibert T
PLoS One. 2023; 18(2):e0279812.
PMID: 36800342
PMC: 9937457.
DOI: 10.1371/journal.pone.0279812.
Radiomics as an emerging tool in the management of brain metastases.
Nowakowski A, Lahijanian Z, Panet-Raymond V, Siegel P, Petrecca K, Maleki F
Neurooncol Adv. 2022; 4(1):vdac141.
PMID: 36284932
PMC: 9583687.
DOI: 10.1093/noajnl/vdac141.
Pregabalin mitigates microglial activation and neuronal injury by inhibiting HMGB1 signaling pathway in radiation-induced brain injury.
Zhang Z, Jiang J, He Y, Cai J, Xie J, Wu M
J Neuroinflammation. 2022; 19(1):231.
PMID: 36131309
PMC: 9490947.
DOI: 10.1186/s12974-022-02596-7.
Bevacizumab is an effective treatment for symptomatic cerebral necrosis after carbon ion therapy for recurrent intracranial malignant tumours: A case report.
Liu R, Luo H, Zhang Q, Sun S, Liu Z, Wang X
Mol Clin Oncol. 2022; 17(1):114.
PMID: 35747599
PMC: 9204208.
DOI: 10.3892/mco.2022.2547.
Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma.
Vaios E, Batich K, Buckley A, Dunn-Pirio A, Patel M, Kirkpatrick J
Oncotarget. 2022; 13:576-582.
PMID: 35359747
PMC: 8963718.
DOI: 10.18632/oncotarget.28222.
Low-Dosage Bevacizumab Treatment: Effect on Radiation Necrosis After Gamma Knife Radiosurgery for Brain Metastases.
Weng Y, Shen J, Zhang L, Fang Z, Xiao F, Zhang C
Front Surg. 2021; 8:720506.
PMID: 34540887
PMC: 8447901.
DOI: 10.3389/fsurg.2021.720506.
Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review.
Liao G, Khan M, Zhao Z, Arooj S, Yan M, Li X
Front Oncol. 2021; 11:593449.
PMID: 33842309
PMC: 8027305.
DOI: 10.3389/fonc.2021.593449.
Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.
Khan M, Zhao Z, Arooj S, Liao G
BMC Cancer. 2021; 21(1):167.
PMID: 33593308
PMC: 7885379.
DOI: 10.1186/s12885-021-07889-3.
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.
Winter S, Loebel F, Loeffler J, Batchelor T, Martinez-Lage M, Vajkoczy P
Neuro Oncol. 2019; 21(9):1118-1130.
PMID: 30828724
PMC: 7594558.
DOI: 10.1093/neuonc/noz048.
Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues.
Zhuang H, Shi S, Yuan Z, Chang J
Mol Cancer. 2019; 18(1):21.
PMID: 30732625
PMC: 6367784.
DOI: 10.1186/s12943-019-0950-1.
Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients.
Loganadane G, Dhermain F, Louvel G, Kauv P, Deutsch E, Le Pechoux C
Front Oncol. 2018; 8:336.
PMID: 30234011
PMC: 6134016.
DOI: 10.3389/fonc.2018.00336.
Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab.
Goyal P, Tenenbaum M, Gupta S, Kochar P, Bhatt A, Mangla M
Quant Imaging Med Surg. 2018; 8(3):268-279.
PMID: 29774180
PMC: 5941208.
DOI: 10.21037/qims.2018.04.05.
Preclinical MRI: Studies of the irradiated brain.
Garbow J, Tsien C, Beeman S
J Magn Reson. 2018; 292:73-81.
PMID: 29705034
PMC: 6029718.
DOI: 10.1016/j.jmr.2018.03.011.
Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with Bevacizumab.
Bahrami N, Piccioni D, Karunamuni R, Chang Y, White N, Delfanti R
AJNR Am J Neuroradiol. 2018; 39(6):1017-1024.
PMID: 29622553
PMC: 6002890.
DOI: 10.3174/ajnr.A5620.
Inhibitors of HIF-1α and CXCR4 Mitigate the Development of Radiation Necrosis in Mouse Brain.
Yang R, Duan C, Yuan L, Engelbach J, Tsien C, Beeman S
Int J Radiat Oncol Biol Phys. 2018; 100(4):1016-1025.
PMID: 29485043
PMC: 6389273.
DOI: 10.1016/j.ijrobp.2017.12.257.
